$0.7
0.0%
Downside
Day's Volatility :10.21%
Upside
10.21%
20.94%
Downside
52 Weeks Volatility :88.07%
Upside
84.91%
Period | Allurion Technologies Inc | Index (Russel 2000) |
---|---|---|
3 Months | -0.71% | 0.0% |
6 Months | -64.07% | 0.0% |
1 Year | -82.75% | 0.0% |
3 Years | -89.79% | -27.4% |
Market Capitalization | 45.4M |
Book Value | -$1.47 |
Earnings Per Share (EPS) | -0.78 |
Wall Street Target Price | 2.38 |
Profit Margin | -78.56% |
Operating Margin TTM | -67.53% |
Return On Assets TTM | -83.88% |
Return On Equity TTM | 0.0% |
Revenue TTM | 47.6M |
Revenue Per Share TTM | 1.03 |
Quarterly Revenue Growth YOY | -9.2% |
Gross Profit TTM | 0.0 |
EBITDA | -65.3M |
Diluted Eps TTM | -0.78 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.28 |
EPS Estimate Next Year | -0.42 |
EPS Estimate Current Quarter | -0.24 |
EPS Estimate Next Quarter | -0.14 |
What analysts predicted
Upside of 240.0%
Sell
Neutral
Buy
Allurion Technologies Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Allurion Technologies Inc | 4.99% | -64.07% | -82.75% | -89.79% | -89.79% |
Stryker Corporation | 6.92% | 11.1% | 34.19% | 33.92% | 83.79% |
Boston Scientific Corp. | 2.4% | 17.72% | 65.69% | 99.4% | 112.28% |
Edwards Lifesciences Corp. | 1.87% | -23.4% | -1.17% | -45.0% | -16.12% |
Abbott Laboratories | 3.03% | 10.01% | 23.21% | -7.89% | 40.06% |
Medtronic Plc | 3.53% | 10.02% | 24.32% | -26.75% | -15.63% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Allurion Technologies Inc | NA | NA | NA | -0.28 | 0.0 | -0.84 | NA | -1.47 |
Stryker Corporation | 39.37 | 39.39 | 2.58 | 12.05 | 0.19 | 0.07 | 0.01 | 52.86 |
Boston Scientific Corp. | 70.02 | 70.11 | 1.55 | 2.46 | 0.09 | 0.05 | NA | 14.05 |
Edwards Lifesciences Corp. | 28.26 | 27.86 | 6.12 | 2.53 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 36.09 | 35.68 | 2.28 | 4.67 | 0.15 | 0.06 | 0.02 | 22.94 |
Medtronic Plc | 30.27 | 29.99 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Allurion Technologies Inc | Buy | $44.6M | -89.79% | NA | -78.56% |
Stryker Corporation | Buy | $140.0B | 83.79% | 39.37 | 16.34% |
Boston Scientific Corp. | Buy | $124.9B | 112.28% | 70.02 | 11.26% |
Edwards Lifesciences Corp. | Buy | $40.2B | -16.12% | 28.26 | 65.86% |
Abbott Laboratories | Buy | $205.7B | 40.06% | 36.09 | 13.99% |
Medtronic Plc | Buy | $115.5B | -15.63% | 30.27 | 12.06% |
Insights on Allurion Technologies Inc
Revenue is up for the last 3 quarters, 8.23M → 11.76M (in $), with an average increase of 16.3% per quarter
Netprofit is down for the last 2 quarters, 5.58M → -2.16M (in $), with an average decrease of 138.7% per quarter
In the last 1 year, Boston Scientific Corp. has given 65.7% return, outperforming this stock by 148.4%
Organization | Allurion Technologies Inc |
Employees | 501 |
CEO | Dr. Shantanu K. Gaur M.D. |
Industry | Miscellaneous |
Cactus Acquisition Corp 1 Ltd
$0.70
-4.94%
Rigel Resource Acquisition Corp
$0.70
-4.94%
Ft Energy Income Partners Strategy Etf
$0.70
-4.94%
Tian Ruixiang Holdings Ltd
$0.70
-4.94%
Invsc Bulletshares 2032 Corp
$0.70
-4.94%
Schwab International Dividend Equity Etf
$0.70
-4.94%
Fitell Corp
$0.70
-4.94%
Estrella Immunopharma Inc
$0.70
-4.94%
Abrdn Income Credit Strategies Fund
$0.70
-4.94%